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Summary sentence 
 
This work highlights a microRNA replacement therapy as a therapeutic option 
for tendon injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Abstract 
Tendon injuries (tendinopathies) are common in human and equine athletes 
and characterised by dysregulated collagen matrix resulting in tendon 
damage. We have previously demonstrated a functional role for miR29a as a 
post-transcriptional regulator of collagen 3 expression in murine and human 
tendon injury. Given the translational potential, we designed a randomised, 
blinded trial to evaluate the potential of a miR29a replacement therapy as a 
therapeutic option to treat tendinopathy in an equine model which closely 
mimics human disease. Tendon injury was induced in the superficial digital 
flexor tendon (SDFT) of 17 horses. Tendon lesions were treated one week 
later with an intralesional injection of miR29a or placebo. miR29a treatment 
reduced collagen 3 transcript levels at week 2 with no significant changes in 
collagen 1. Relative lesion cross-sectional area was significantly lower in 
miR29a tendons compared to control tendons. Histology scores were 
significantly better for miR29a treated tendons compared to control tendons. 
This data supports the mechanism of miRNA-mediated modulation of the 
early pathophysiologic events that facilitate tissue remodelling in the tendon 
after injury and provides strong proof of principle that a locally delivered 
miR29a therapy improves early tendon healing.  
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Introduction 
 
Dysregulated tissue repair and inflammation characterize many 
musculoskeletal pathologies, including tendon disorders in both human and 
equine practice1-4.  Tendon injuries remain a significant problem in equine 
practice comprising the most common musculoskeletal injury in racehorses. 
Injury to the SDFT, most often involving the metacarpal segment of the 
forelimb tendon, is one of the most frequent causes of lameness of athletic 
horses internationally with a reported frequency of 10–30%5,6. 
The immune system plays a crucial role in the regulation of tissue 
remodelling by coordinating complex signalling networks that facilitate 
transcriptional regulation of extracellular matrix (ECM) components as an 
adaptive response to environmental cues. Inflammatory mediators are 
considered crucial to the onset and perpetuation of tendinopathy7-9. 
Expression of various cytokines has been demonstrated in inflammatory cell 
lineages and tenocytes, suggesting that both infiltrating and resident 
populations participate in pathology10-12. Additionally, evidence suggests a 
balance exists between pro inflammatory and pro resolving mediators that 
may ultimately define the extent to which equine tendinopathy develops and 
subsequently repairs13,14. 
 Recent work has identified the importance of tissue microenvironments 
and the interaction immune mediators in inflammatory/ stromal cell 
crosstalk15. MicroRNAs (miRNAs) are small, non-coding RNAs that suppress 
gene expression at the post-transcriptional level by inhibiting translation 
and/or inducing mRNA degradation16. A single miRNA can regulate the 
expression of multiple target mRNAs through sequence binding. Emerging 
studies highlight miRNAs as key epigenetic regulators of integrated 
mammalian cell functions17,18. Specific miRNAs have emerged that 
particularly regulate cytokine networks while orchestrating proliferation and 
differentiation of stromal lineages that determine ECM composition19. miRNAs 
have provoked extensive interest as regulators of musculoskeletal diseases, 
although their precise contributions to complex disease pathways remains 
uncertain20. miR-210 has been reported as a crucial regulator of 
angiogenesis21, a key factor in tendon disease, and it accelerated healing of 
tendon in an Achilles tendon rodent injury model22 while additionally causing 
upregulation of vascular endothelial factor, fibroblast growth factor and type I 
collagen in the same model system. miRNAs designed and engineered 
according to genetic sequences of transforming growth factor β1 (TGFβ1) and 
injected in the chicken tendon injury model achieved downregulation of 
TGFβ1 expression in vitro and in vivo23. Some compounds can regulate 
endogenous miRNA expression, which may confer therapeutic value. One 
such study demonstrated that miR29b mediated chitosan-induced prevention 
of tendon adhesion after rodent Achilles tendon injury surgery by regulating 
the TGFβ1–Smad3 pathway24.  
 We have previously demonstrated a functional role for miR29a as a 
post-transcriptional regulator of collagen in murine and human tendon injury25. 
Given the translational potential we designed a randomized blinded trial to 
evaluate the potential for miR29a replacement therapy as a therapeutic option 
to treat tendinopathy utilising an equine collagenase model considered 
analogous to human tendon disease.  
 
  
Results 
 
miR29a expression in equine tendinopathy model 
 
We found that miR29a was significantly (p<0.01) downregulated throughout 
the time course of the induced tendinopathy model (Figure 1a).  Additionally, 
we noted a significant differential regulation of collagen 1 and 3 transcripts 
throughout the time course (Figure 1b &c). The most notable changes were in 
collagen 3 transcript early in the model, which was upregulated 80 fold at 
week 3 and 25 fold at week 5 post induction which was maintained >30 fold at 
weeks 9 and 17. This was in contrast to Collagen 1 transcripts which were 
upregulated significantly less (p<0.05) at early time points (13 fold at 3 weeks, 
9 fold at 5 weeks, p<0.05 versus collagen 3 transcript) which was reversed at 
weeks 9 (26 fold) and 17 (24 fold). 
 
Regulation of collagen expression by miR29a is conserved in equine 
tenocytes 
 
Sequence analysis revealed that the miR29a binding sites in collagen 1 and 3 
transcripts previously described in humans and mice are conserved in horses 
(Figures 1 d-e). To confirm the activities of these predicted miR29a binding 
sites a series of luciferase reporter constructs containing wild-type and 
mutated miR29a-bindings sites were made. Over-expression of miR29a 
decreased luciferase activity in HEK cells transfected with in wild-type but not 
mutated plasmids demonstrating that both col1a1 and col3a1 are bone fide 
miR29a targets (Figure 1 f-g).  To test whether miR29a indeed regulates the 
levels of candidate target mRNAs in disease-relevant cells, we transfected 
primary equine tenocytes with miR29a mimic. miR29a manipulation 
selectively regulated collagen 3 (p<0.01) but not collagen 1 mRNA (Figure 2 
a-b). This in is keeping with our previous observations in human tenocytes 
which showed that miR29a binding sites are excised from collagen 1 
transcripts due to the use of an alternative proximal polyadenylation signal25. 
Comparison of the polyA sites in both col1a1 and col3a1 showed that the 
polyadenylation signals and the sequences that flank them are identical in 
other mammalian species including horses and dogs, suggesting that this 
alternative polyadenylation is conserved in these species (Figure 2 c-f). To 
test this, the 3’ ends of collagen1 and 3 transcripts were characterised using 
3’RACE. Sequence analysis showed that both collagen1 and 3 utilised the 
same conserved polyadenylation signals found in the corresponding human 
transcripts (Figure 2 g-h). Together these results support the idea of common 
molecular pathogenic process driven by the loss of miR29a in the 
development of tendinopathy in human and horses. This finding raises the 
possibility that re-introduction of miR29a could have significant therapeutic 
benefit in the healing of tendon lesions. 
 
 
miR29a treatment improves early tendon healing  
 
The study consisted of two randomly assigned groups: group A (miRNA29a 
mimic; n =9 ; 5 male, 4 female; miRNA29a) and group B (placebo treated 
tendons; n = 8; 5 male, 3 female; CONT) with the study timeline detailed in 
Figure 3a. 
 
Quantitative PCR : miR29a treatment specifically suppressed collagen 3 at 
week 2 (p=0.01) and showed a trend toward reduction at week 4 (p=0.06) 
(Figure 3 b-c). Importantly in keeping with our in vitro data miR29a treatment 
caused no significant changes in collagen 1 at any time points in this equine 
model.  
 
Ultrasound:  Normalized lesion CSA was significantly lower in miR29a treated 
tendons compared to control tendons at t = 6,12 &16 weeks (p<0.05) and 
showed a trend for smaller CSA at t = 8 weeks (p = 0.1) (Figure 4a). 
Normalized relative lesion CSA was significantly lower in miR29a tendons 
compared to control tendons at t = 6,8,12 &16 weeks (p<0.05) (Figure 4b). 
Subjective blinded US scoring showed significant less SC thickening and 
more normal tissue architecture at week 12 & 16 in the miR29a tendons 
compared to control tendons (Figure 4c and Table 1). 
 
MRI:  Tendon lesions were identified by increased T2-weighted signal 
intensity in all tendons (Figure 5a-b). Tendon CSA made on MR images were 
not significantly different between groups (Figure 5b). However, there was a 
trend (p=0.07) of reduced relative CSA and reduced lesion CSA of miR29a 
treated tendons compared to that of control tendons at weeks 4,6,12 &16. 
Additionally, the T2 relaxation times was significantly (p<0.05) greater in 
control tendons at 12 weeks (mir29a; 57.9 ± 15, control; 218.9 ± 74.6) (Figure 
5c). 
 
Gross dissection & Histology:  No peritendinous adhesions were noted during 
dissection in either group. Cumulative histology scores were significantly 
better for miR29a treated tendons compared to control tendons (Figure 6a 
and b) at weeks 2 & 16 utilizing the modified Bonar score (Cell density, 
vascularity, linear fibre and polarised collagen). Tendons from both groups 
were visibly enlarged, centered at 16 cm DACB, and had minimal peri-
tendinous reaction. Although no scores were assigned, miR29a treated 
tendons appeared smaller at 16 cm DACB, had less peri-tendinous reaction 
and treatment injection sites were less obvious (Figure 6c).  
 
 
  
 Discussion 
The molecular processes underpinning the development of collagen 3 
over-production seen in tendinopathy have been evolutionarily conserved in 
mammalian species demonstrating their biological importance. Here we 
showed that the injury-induced loss of miR29a from tenocytes previously 
reported in humans also occurs in collagenase-induced tendinopathy in 
horses and that this inversely correlates with collagen 3 expression. We have 
demonstrated that as is the case in humans, miR29a has the potential to 
target both collagen 1 and 3. Despite this, only collagen 3 expression is 
decreased by the miR29a overexpression in equine tenocytes. A detailed 
characterisation of col1a1 and col3a1 transcripts reveals that col1a1 utilises 
an alternative polyA signal that truncates its 3’UTR with the loss of all three 
miR29 binding sites. This means that in equine tenocytes only collagen 3 is 
regulated by miR29a, a situation that mirrors that previously described in 
humans. These findings raised the possibility that re-introduction of miR29a 
into the tendinopathic environment could reduce collagen 3 production leading 
to improved tendon healing. To test this, we designed a blinded, placebo-
controlled, experimental trial an equine model that revealed clinically relevant 
improvement in the healing of earlt tendon injury after intralesional injection of 
miR29a. 
Recent studies highlight miRNAs as key regulators of leukocyte 
function and differentiation of stromal cells that determine extracellular matrix 
composition20,26,27. Our data demonstrate a functional role for miR29a as a 
post-transcriptional regulator of collagen in equine tendon injury. Despite its 
many similarities, the collagenase model of tendon injury does not totally 
mimic the insidious and degenerate etiopathogenesis of many forms of 
naturally occurring tendon injury in man. However, the clinical relevance of 
this model to the final acute disruption after months or years of chronic tendon 
injury, is supported by the evaluation of gross, biochemical and 
histopathological changes, clinical signs, mechanical characteristics, and MRI 
and ultrasonographic findings following the induction of injury28,29. Additionally, 
the collagenase model allows the generation of a homogenous tendon lesion 
in a controlled group of animals and, therefore, improved ability to detect 
differences between treated and control arms of the study. The reduced 
expression of miR29a immediately after tendon injury up until 16 weeks post 
injury induction and concomitant increase in collagen 3:collagen 1 ratio in 
control animals that we report herein further demonstrates the model 
molecularly reflects disease in human and in rodent models of tendinopathy25. 
The regulation of collagens and other extracellular matrices by the miR29 
family has been highlighted in several prior studies17,25,30. Our results now 
show that miR-29a acts as an important repressor to regulate collagen 
expression in equine tendon healing. The molecular understanding of 
increased collagen 3 deposition resulting in biomechanical inferiority and 
degeneration has been largely under investigated in equine tendon disease. 
While it is likely that miR29a targets other important genes31,32 in the 
multifaceted tendon injury mileu, our data suggest that the miR29a is a critical 
driver of the collagen post transcriptional regulation resulting in a key collagen 
switch that remains a major pathological feature of equine tendinopathy. 
Novel quantitative biochemical MRI techniques, such as T2 mapping, have 
been increasingly evaluated for their demonstrated sensitivity in detection of 
earlier biochemical changes (i.e. collagen bril structure, orientation, and water 
content) in various tissues33,34. Thus the variability in T2 mapping of placebo 
treated tendons as compared to miR-29a treated tendons suggest improved 
tissue quality, collagen content and collagen orientation due to miR-29a 
replacement. 
The standard of care for tendon and ligament injury in equine clinical 
medicine is conservative therapy, based on minimizing exercise and anti-
inflammatory medication. Novel methods have focused on regenerative medicine 
approaches with either platelet rich plasma (PRP) or stem cells. None of 
these recent ‘novel’ tendinopathy treatments have provided mechanistic 
insight; thus, their wholehearted adoption in the clinical community is not yet 
apparent. Following PRP in the horse, there is experimental evidence of 
improved histology35, increased neovascularization36 and ultrasound 
appearance37 of treated tendons but clinical evidence has failed to show a 
treatment effect38, similar to the experience in human tendon disease39. 
Following stem cells in the horse, there is experimental evidence of improved 
histology40,41  and clinical evidence for safety42, improved cellularity43  and a 
reduced re-injury rate compared to historical controls44 . The initial 
enthusiasm for stem cells in regenerative medicine was one of tissue specific 
differentiation in that stem cells implanted to a tendon lesion, for example, 
would engraft, become tenocytes and produce tendon matrix. As both basic 
science and clinical data accumulates, it appears that stem cell therapy with 
the mesenchymal stem cell is due to local production of bioactive molecules 
and immune modulation rather than tissue specific differentiation and long-
term engraftment45. Herein, we show that local delivery of miR29a is capable 
of producing comparable and in some cases superior results to PRP or stem 
cell treatment (similar experimental trials) with regard to lesion size and 
histological improvement46,47. Our study appears to mirror the concept of 
earlier lesion resolution and lack of lesion progression at early time points. 
This in conjunction with a concurrent tissue molecular phenotype of reduced 
collagen 3 confirmed macroscopically on T2 mapping provides convincing 
evidence that a miR manipulation can target both inflammatory/matrix 
crosstalk in tendon disease with subsequent lesion resolution. miRNAs have 
several important advantages in that they are bio-developable and comprise 
known sequences that are often highly conserved among species, both 
attractive features from a drug development standpoint.  
There are limitations inherent in our study. The equine model has the 
inability to test therapies in a large number of animals, resulting in a study that 
may be underpowered. This is due to the significant cost of housing, buying 
and caring for these animals and the strong emotional and ethical 
considerations in their use and sacrifice48. We additionally note that due to 
logistical and ethical considerations we were unable to completely age and 
sex match each animal within the treatment and placebo group. As mentioned 
the collagenase model of tendon injury does not totally mimic the naturally 
occurring lesion in man. However, the collagenase model allows the 
generation of a homogenous tendon lesion in a controlled group of animals 
and, therefore, improved ability to detect differences between treated and 
control arms of the study. The equine mid-metacarpal SDFT is a large, weight 
bearing tendon that is easily accessible, is not confined to a synovial sheath, 
and in the equine athlete is commonly affected by naturally occurring over-
stretch tendon injury compounded on previous microfiber disruption, similar to 
tendinopathies of the human Achilles tendon49,50. Finally, we appreciate future 
studies should be conducted to further elucidate the ideal time of 
administration of any equine tendinopathy therapy. These studies would 
contribute to the understanding of when the best therapeutic results are 
obtained and whether it is feasible to prevent further injury when the therapy 
is administered to a still-developing injury. 
 
Conclusion 
 
The present study demonstrated that a microRNA therapy had a favourable 
action in the treatment of tendinopathy by the prevention of the lesion 
progression, improved tendon tissue quality and histopathology comparable to 
current regenerative therapies.  This data supports the mechanism of miRNA-
mediated modulation of the early pathophysiologic events that facilitate tissue 
remodeling in tendon after injury and provides proof of principle that a locally 
delivered miR29a therapy can improve early tendon healing. 
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Methods 
 
Equine model of tendinopathy 
 
Animals  
The data generated in Figures 1 & 2 represent historical RNA tissue samples 
from a previously published model41 and were utilized in the pursuit of RRR.  
Eight adult female Thoroughbred (n = 7) or Thoroughbred cross (n = 1) 
horses, ranging in age from three to seven years, without clinical or 
ultrasonographic evidence of tendon injury were used. All horses had 
undergone rigorous athletic training prior to inclusion in the study. Horses 
were housed separately, in box stalls, and allowed to acclimate to the 
environment for ≥2 weeks prior to study initiation. These animals then 
underwent the tendon injury model as described below. 
 
For the randomised section of the trial seventeen adult Quarter Horse-type 
horses, ranging in age from two to seven years, without clinical or 
ultrasonographic evidence of tendon injury were used. The sample size was 
based on the first authors previously published studies utilizing the 
collagenase model41,51 which showed the largest group should have 8 horses 
to show statistically differences regarding tissue architecture, tendon size, 
tendon lesion size, and tendon linear fibre pattern. Horses were housed 
separately, in box stalls, and allowed to acclimate to the environment for ≥2 
weeks prior to study initiation. All invasive procedures were performed by an 
experienced board certified veterinary surgeon (A.E.W). This study was 
approved by and performed according to guidelines of the University's 
Institutional Animal Care and Use Committee, protocol number 2013-0019 
and all experiments were performed in accordance with relevant guidelines 
and regulations.  
 
 
Tendon injury induction and therapy administration 
Collagenase-induced lesions were created in the tensile region of the 
superficial digital flexor tendon (SDFT) of one randomly selected forelimb 
using filter sterilized bacterial collagenase type I (Sigma, St. Louis, MO, USA) 
as previously described51. Forelimb selection (left or right) was made by a 
coin toss for each horse. One thousand units of collagenase was delivered to 
a columnar physical defect centred within the tensile region of the SDFT 
tendon (16 to 18 cm distal to the accessory carpal bone; DACB) using a 16 
gauge 8.89 cm Weiss Epidural needle with a Tuohy tip (BD, Franklin Lakes, 
NJ, USA) inserted under ultrasonographic guidance, as previously described. 
The study forelimb was bandaged. One week post tendon injury induction (0 
weeks), tendons were injected with 1.5 ml of 67 µM miR29a (based on 
preliminary rodent in vivo studies)  in PBS (modified to include 2’Fluoro and 
2’O-Me nucleotides to increase half-life in serum), or placebo (PBS) via 
ultrasonographically-guided intra-lesional injection in the mid- metacarpal 
lesion with 25 gauge needle entry at 17 cm DACB, in the center of the lesion. 
The needle was directed from palmarolateral to dorsomedial.  
 
Study design 
The study consisted of two randomly assigned groups: group A (miRNA 29a 
mimic; n =9 ; 5 male, 4 female; miRNA29a) and group B (placebo treated 
tendons; n = 8; 4 male, 4 female; CONT). One week after tendon injury by 
collagenase injection, treatment injections were performed. A subset of 
animals were euthanized, and tissues were collected at two, four and sixteen 
weeks. Other than an on-site control officer, all investigators were blinded to 
treatment group identification until the study was completed and all assays 
were performed. Treatment group (A or B) was revealed for statistical 
analysis. Once all analyses were completed, treatment group identification 
(miRNA29a or CONT) was disclosed. 
 
None of the horses had been previously athletically trained. All horses had 
been housed at pasture in a group setting until 2 weeks prior to the start of the 
study, at which point they were housed individually in box stalls until study 
termination. Eight weeks post treatment injection horses began daily in-hand 
walking exercise for 5 minutes each day, which was increased to 10 minutes 
a day for weeks 12-16. There were pre-existing musculoskeletal abnormalities 
in 2 horses: one horse (mir29a group, 16 week horse) had a mild flexural limb 
deformity (club foot) and one horse had delayed release of the patella (control 
group, 16 week horse). One horse (mir29a group,16 week horse) got loose 
from her handler during the 8th week post-treatment injection and galloped 
free for 3 minutes. Other than one horse that was treated for colic prior to 
study initiation (mir29a group, week 4), none of the horses had a history of 
prior diseases or treatments other than castration, none required treatment for 
other diseases or injuries during the study and there was no evidence of prior 
or concomitant diseases during post mortem exam in any of the horses. The 
age, sex and weight of each animal is given in Table 2. 
 
 
 
Ultrasound 
Ultrasound examinations were performed prior to admission to the study 
(baseline) and at t = 0, 2, 4, 6, and 8, 12 and 16 weeks after treatment 
injection. Ultrasound imaging was performed by a board-certified internal 
medicine specialist (D.S.) using a hospital based non-portable ultrasound 
machine (MyLab 70, Esoate, Florance, Italy) equipped with a high frequency 
(4-13 MHz) linear array probe for equine tendon (LA523 Vet, Esoate, 
Florence, Italy). A template was used to ensure accurate repetition of tissue 
gain settings, focus, and depth of tissue penetration. Longitudinal and 
transverse ultrasound images were acquired and tendon cross-sectional area 
(TCSA), lesion cross-sectional area (LCSA), and a longitudinal linear fiber 
pattern score were measured by the same ultrasonographer at 16 cm DACB. 
The LCSA as a percentage of TCSA was calculated for relative lesion cross-
sectional area (RLCSA). Tendons were also scored as having a normal shape 
(yes/no) and overlying subcutaneous thickening (yes/no). 
 
Magnetic resonance imaging 
Magnetic resonance imaging was performed at two, four, six, eight, twelve 
and sixteen weeks after treatment injection using a 3.0 Tesla MRI system 
(Siemens Magnetom Verio) using a 15-channel knee coil (Quality 
Electrodynamics) and positioned in left lateral recumbency with a marker 
placed at 17 cm DACB.  Sagittal and transverse plane T2 maps (i.e. turbo 
spin echo sequence with multiple echo times of 15.2, 30.4, 45.6, 60.8, 76, 
91.2 milliseconds) and transverse plane STIR (short tau inversion recovery) 
images were acquired. 
 
Tissue harvest  
Horses were euthanized by pentobarbital overdose at two, four and sixteen 
weeks post treatment injection. Limbs were dissected under RNase free 
conditions and samples were collected from the center of the tendon lesion at 
16 cm DACB extending into the surrounding normal tendon. Samples were 
snap-frozen in liquid nitrogen, pulverized in a freezer-mill and stored at -80°C 
until use, or fixed in 4% paraformaldehyde at 4°C f or 72 hours.  
 
Equine tendon explants 
To establish tendon explant cultures, the superficial digital flexor tendon was 
aseptically excised from the midmetacarpal region of both forelimbs of 3 
horses (aged 2 to 5 years) without evidence or history of tendon injury; the 
horses were euthanized for reasons unrelated to the study. Tendons were 
determined to be normal on the basis of findings via palpation, gross 
examination, and later dissection for explant culture. Following collection, the 
tendon segments were maintained in culture medium during the removal of 
the paratenon. The tendon segments were then sectioned into 5 X 5 X 4-mm 
blocks and evenly distributed in 12-well plates for explant culture of tenocytes. 
Segments were maintained for 6 days at 37 degrees C, 5% CO2 and 70% 
humidity in complete medium (penicillin [50 U/mL]; streptomycin [50 µg/mL]; 
ascorbic acid [100 µg/mL]; and 2% fetal bovine serum) to allow explant 
culture of tenocytes. After 6 days, each explant was divided, and a portion 
was snap-frozen in liquid nitrogen and pulverized for RNA isolation with a 
phenol-guanidine isothiocyanate reagent. A cross-sectional edge was fixed in 
4% paraformaldehyde, embedded in paraffin, and sectioned for H&E staining.  
Equine tenocytes were transfected with Hsa-miR-29a-3p and miRIDIAN 
microRNA Negative Control #1 miRNA mimics using Dharmafect 3 
(Dharmacon). Transfection efficiency was assessed using miRIDIAN™mimic 
Transfection control Dy-547 (Dharmacon). We determined the transfection 
efficiency using a fluorescently labelled miR29a mimic. This was performed 
initially in cultured human tenocytes where the uptake of labelled miR29a was 
monitored by fluorescent microscopy. Additionally, we assessed uptake of 
fluorescent miR29a when injected directly into the murine patellar tendon. In 
both cases miR29a was readily taken up by tenocytes with transfection 
efficiency >85%. 
 
 
 
RNA and DNA isolation and qPCR 
The cells isolated from experiments and freezer mill pulverized tendon 
samples from the in vivo trial were placed in Trizol before mRNA extraction. 
QIAgen mini columns (Qiagen) were used for the RNA clean-up with an 
incorporated on column DNAse step as per the manufacturer’s instructions. 
cDNA was prepared from RNA samples according to AffinityScript (Agilent 
Technologies) multiple temperature cDNA synthesis kit as per the 
manufacturer’s instructions. Real-time PCR was performed using SYBR green 
or Taqman FastMix (Applied Biosystems,) according to whether a probe was 
used with the primers. The cDNA was diluted 1 in 5 using RNase-free water. 
Each sample was analysed in triplicate. Primers (Integrated DNA 
Technologies, Belgium) were as follows:  
GAPDH Fw 5'- AGAAGGAGAAAGGCCCTCAG -3' and Rev 5'- 
GGAAACTGTGGAGGTCAGGA -3', Beta Actin Fw 5'- 
AAGGGACTTCCTGTAACAATGCA -3' and Rev 5'- 
CTGGAACGGTGAAGGTGACA -3', Col1a1 Fw 5'- 
CAGACTGGCAACCTCAAGAA -3' and Rev 5'- 
CAGACTGGCAACCTCAAGAA -3', Col3a1 Fw 5'- 
CTGGAGGATGGTTGCACTAAA -3' and Rev 5'- 
CACCAACATCATAGGGAGCAATA -3' 
 
 
All mRNA and miRNA data sets represent fold change in gene expression 
compared with designated control utilizing housekeeping genes GAPDH, 18S 
or U6 as detailed in Figure legend. 
 
RNA isolation and quantitative PCR of miRNA 
Total RNA was isolated by miRNeasy kit (Qiagen). miScript Reverse 
Transcription Kit (Qiagen) was used for cDNA preparation. TaqMan mRNA 
assays (Applied Biosystems) or miScript primer assay (Qiagen) were used for 
quantitative determination of the expression of miR-29a (MS00001701).  
Expressions of U6B small nuclear RNA or β-actin were used as endogenous 
controls. 
 
Luciferase assay  
Conserved miR29a binding sites in the 3'UTRs of equine col1a1 and col3a1 
were identified using TargetScan. The regions corresponding to these sites 
were synthesised as G-blocks (Integrated DNA Technologies, Belgium) and 
inserted downstream of the luciferase ORF in pmiRGLO (Promega) using 
Gibson Assembly (New England Biolabs). The equivalent regions in which the 
seed regions of predicted miR29a binding sites were deleted were created in 
parallel. Plasmids were transfected into HEK293 cells along with miR29a or 
scrambled control mimics (Thermofisher) using Attractene (Qiagen). 
Luciferase activities were measured using Dual-Glo luciferase assay 
(Promega).  
 
3' Rapid Extension of cDNA Ends 
3’UTR sequences of col1a1 and col3a1 transcripts were generated by 3’ 
Rapid Extension of cDNA Ends (3’RACE) by using RNA prepared from equine 
tenocytes. The primers used were as follows: col1a1 GSP1 5'- 
CCCTGGAAACAGACAAACAAC -3', col1a1 GSP2 5'- 
CAGACAAACAACCCAAACTGAA-3', col3a1 GSP1 5'-
AGGCCGTGAGACTACCTATT-3' and col3a1 5'-GSP2 
CTATGATGTTGGTGGTCCTGAT-3'. The resulting PCR products were 
cloned into pCR2.1 TOPO (Invitrogen) for sequencing. 
 
Histology 
Fixed longitudinal tissue sections were embedded in paraffin, sectioned and 
stained with hematoxylin and eosin (H&E) or Picrosirius Red and examined 
under white light and polarized light microscopy. All slides were examined by 
a board certified veterinary pathologist, specialized in musculoskeletal 
pathology (R.P.). Sections were sequentially examined across and down the 
entire tendon section, under low power and high power (10 fields) where 
appropriate for cell detail, to derive a complete histologic impression. All 
tendon parameters were scored from l (normal) to 4 (severe changes) for: 
tenocyte shape, tenocyte density, free hemorrhage, neovascularization, 
perivascular cuffing, collagen fiber linearity, collagen fiber uniformity and 
polarized light crimping as previously described51. 
 
Statistical analyses 
All results are shown as mean ± standard error of the mean and all statistical 
analysis was performed using Student’s t-test, ANOVA (analysis of variance) 
test or Mann–Whitney test U-test, as indicated in figure legends, using the 
Graph Pad Prism 5 software. A p value of <0.05 was considered statistically 
significant.  
Figure legends 
 
Figure 1 
miR29a is dysregulated in equine tendinopathy and targets col1a1 and 
col3a1 via conserved binding sites  
(a) miR29a, (b) Col3a1 and (c) Col1a1 expression in equine tendinopathy 
model at 3,5,9 & 17 weeks post lesion induction. Data for mRNA are total 
copy number of gene versus GAPDH housekeeping gene in duplicate 
samples. *p<0.05, **p<0.01 versus control (ANOVA).  
(d-e) sequence alignments of miR29a with its predicted binding sites in col1a1 
and col3a1. Seed regions are shown in red. (f-g) Luciferase activity in 
HEK293 cells co-transfected with wild-type or mutated col1a1 or col3a1 
3'UTR luciferase reporter and miR29a or scrambled control mimics. Activities 
were normalised to control and values expressed as % of scrambled controls, 
(n =3). Data analyzed by Mann Whitney U Test, *p<0.05 versus scrambled 
control 
 
Figure 2  
miR29a preferentially targets col3a1 over col1a1 in equine tenocytes 
Copies col1a1 (a) and col3a1 (b) transcripts levels after transfection with 
miR29a and scrambled (control) mimics normalized to 106 copies of 18S. This 
was repeated in three independent experiments. **p<0.01 versus scrambled 
control. (Student’s t-test). (c-d) sequence alignments of predicted col1a1 and 
col3a1 polyadenyation signals (underlined). (e-f) Diagram of alternative 
polyadenylated 3UTRs from col1a1 and col3a1, showing the positions of 
miR29a-binding sites and predicted polyadenylation signals (pA). (g-h) 
3'RACE sequences of col1a1 and col3a1 transcripts cloned from equine 
tenocytes. Stop codon in red, polyA signals underlined, polyA tail in bold and 
miR29a binding site shown in blue. 
 
 
 
 
 
Figure 3 
miR29a treatment targets col3a1 with no effect on col1a1 in early tendon 
healing in vivo     
(a) Study timeline, (b-c) Quantitative PCR of col1a1 and col3a1of tendon 
lesion samples expressed as copies per 10,000 copies of GAPDH. Week 2 
n=3, week 4 n=2 and week 16 n=4. **p<0.01 versus scrambled control. (One 
way ANOVA). 
 
Figure 4  
Ultrasound tendon healing post miR29a treatment 
Normalized (a) lesion and (b) lesion relative to tendon cross-sectional area 
(CSA) for miR29a and placebo treated tendons (control) treated tendons at 
time points post treatment injection in weeks. *p<0.05, versus control (one 
tailed Student’s t-test) (c) Transverse and longitudinal ultrasound images 16 
cm distal to the accessory carpal bone, sixteen weeks post treatment with 
miR29a or placebo treated tendons.  
 
Figure 5  
MRI tendon healing post miR29a treatment 
Normalized (a) lesion to tendon cross-sectional area (CSA) for miR29a and 
placebo treated tendons (control) treated tendons at time points post 
treatment injection in weeks. (b)Transverse T1 MR images at 17 cm distal to 
the accessory carpal bone sixteen weeks after treatment injection with 
miR29a or placebo treated tendons. (c) MRI T2 r mapping relaxation times for 
miR29a and placebo treated tendons (control) at time points post treatment 
injection in weeks. *p<0.05, versus control (one tailed Student’s t-test) 
 
Figure 6 
Histology and tissue architecture post miR29a treatment 
(a) Histological scoring utilizing the modified Bonar Score (Cell density, 
vascularity, linear fibre and polarised collagen) at 2,4 and 16 weeks. * p<0.05 
miR29a versus controls (Mann Whitney U test) (b) 200× magnification of 
longitudinal sections of superficial digital flexor tendon stained Picrosirius Red 
sixteen weeks after treatment injection with mir29a or placebo treated 
tendons. Bars = 200µm. (c) Cross sectional gross pathology images from 
miR29a treated tendon versus control tendon at 16 weeks post treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1 
Subjective ultrasound scoring for subcutaneous thickening and abnormal 
tendon shape. Each ultrasound image was scored by a blinded assessor 
(D.S.) for subcutaneous thickening (yes/no) or abnormal tendon shape 
(yes/no) at the site of induced injury. Percentage of subjects in brackets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SC Thickening Abnormal Shape
Weeks 29a Control 29a Control
0 4/9 (44) 4/8 (50) 7/9 (78) 7/8 (88)
2 4/9 (44) 4/8 (50) 8/9 (89) 7/8 (88)
4 3/7 (43) 3/6 (50) 2/7 (29) 5/6 (83)
6 3/4 (75) 4/4 (100) 2/4 (50) 4/4 (100)
8 3/4 (75) 4/4 (100) 2/4 (50) 4/4 (100)
12 1/4 (25) 3/4 (75) 2/4 (50) 4/4 (100)
16 1/4 (25) 4/4 (100) 1/4 (25) 4/4 (100)
 Week Group Age Sex Weight(kg) Height(cm) 
2 A 4 M 413 142 
2 A 3 M 394 147 
2 A 3 G 412 147 
2 B 4 M 468 147 
2 B 6 G 558 160 
4 A 6 G 404 142 
4 A 6 G 432 147 
4 B 2 M 492 157 
4 B 2 M 484 155 
16 A 3 M 408 147 
16 A 2 G 424 147 
16 A 2 M 436 147 
16 A 4 G 466 152 
16 B 4 M 452 150 
16 B 3 M 402 147 
16 B 6 G 420 147 
16 B 2 M 443 145 
 
Table 2  
Demographics of horses utilized in study. Group A (mir29a treated), Group B 
(control, PBS). 
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